Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Niagen Bioscience, Inc.CDXC · Entity 6146 | Director | June 17, 2021 | June 22, 2021 |
| VBI VACCINES INC.VBIV · Entity 154844 | Director · CEO, President | April 18, 2017 | April 19, 2017 |
| VBI Vaccines Inc/BCVBIV · Entity 111039 | Director · CEO, President | July 27, 2023 | July 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Niagen Bioscience, Inc.
Report date June 17, 2021 · Filed June 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.99 · Expires 2031-06-16 | Direct | 20,000 |
Reported balance
After 2021-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-17 · Grant · Acquired 20,000 · Balance 20,000 F1: Options vest 100% on June 17, 2022 |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest 100% on June 17, 2022
VBI VACCINES INC.
Report date April 18, 2017 · Filed April 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy Common Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $3.79 · Expires 2027-01-26 | Direct | 20,000 |
Reported balance
After 2017-04-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-18 · Grant · Acquired 20,000 · Balance 20,000 F1: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 26, 2017 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated April 18, 2017 (the "Option Agreement"). The options vest and become exercisable in 48 equal monthly installments beginning on the first day of the month following the Grant Date. F2: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 26, 2017 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated April 18, 2017 (the "Option Agreement"). The options vest and become exercisable in 48 equal monthly installments beginning on the first day of the month following the Grant Date.
F2: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement.
VBI Vaccines Inc/BC
Report date July 27, 2023 · Filed July 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy Common Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2033-07-27 | Direct | 70,000 |
Reported balance
After 2023-07-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-27 · Grant · Acquired 70,000 · Balance 70,000 F1: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on July 27, 2023 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated July 27, 2023 (the "Option Agreement"). 25% of the options vest and become exercisable on the one-year anniversary of the Grant Date, with the remaining 75% of the options vesting and becoming exercisable in 24 equal monthly installments beginning on the first day of the month following the one-year anniversary of the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on July 27, 2023 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated July 27, 2023 (the "Option Agreement"). 25% of the options vest and become exercisable on the one-year anniversary of the Grant Date, with the remaining 75% of the options vesting and becoming exercisable in 24 equal monthly installments beginning on the first day of the month following the one-year anniversary of the Grant Date, subject to the reporting person's employment on the relevant vesting date.
F2: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2023 Filed Jul 28, 2023 18:30 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 70,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001493152-23-025954 · ownership.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Shares · 70,000 shares Expires 2033-07-27 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on July 27, 2023 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated July 27, 2023 (the "Option Agreement"). 25% of the options vest and become exercisable on the one-year anniversary of the Grant Date, with the remaining 75% of the options vesting and becoming exercisable in 24 equal monthly installments beginning on the first day of the month following the one-year anniversary of the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 17:02 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 100,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001493152-23-002981 · ownership.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2033-01-26 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 26, 2023 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 26, 2023 (the "Option Agreement"). 25% of the options vest and become exercisable on the one-year anniversary of the Grant Date, with the remaining 75% of the options vesting and becoming exercisable in 24 equal monthly installments beginning on the first day of the month following the one-year anniversary of the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 17:40 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 800,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001493152-22-002773 · ownership.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Shares · 800,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 27, 2022 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 27, 2022 (the "Option Agreement"). 25% of the options vest and become exercisable on the one-year anniversary of the Grant Date, with the remaining 75% of the options vesting and becoming exercisable in 24 equal monthly installments beginning on the first day of the month following the one-year anniversary of the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:28 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $9.99 | $0.00 |
DisclosureSEC source: 0001628280-21-012676 · wf-form4_162439725270272.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: Options vest 100% on June 17, 2022 Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 18:09 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 1,000,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001493152-21-002138 · ownership.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Shares · 1,000,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 27, 2021 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 27, 2021 (the "Option Agreement"). 25% of the options vest and become exercisable on the one-year anniversary of the Grant Date, with the remaining 75% of the options vesting and becoming exercisable in 24 equal monthly installments beginning on the first day of the month following the one-year anniversary of the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 17:15 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 425,200 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001493152-20-012553 · ownership.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,200 Underlying: Common Shares · 425,200 shares Expires 2030-07-01 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on July 1, 2020 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated July 1, 2020 (the "Option Agreement"). 25% of the options vest and become exercisable on the one-year anniversary of the Grant Date, with the remaining 75% of the options vesting and becoming exercisable in 24 equal monthly installments beginning on the first day of the month following the one-year anniversary of the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 01:21 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001415889-20-001667 · form4-06222020_060659.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: Options vest 100% on June 19, 2021. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 17:19 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 500,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001493152-20-001072 · ownership.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Shares · 500,000 shares Expires 2030-01-22 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 22, 2020 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 22, 2020 (the "Option Agreement"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| September 30, 2019 Filed Sep 30, 2019 16:22 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | PurchaseCommon Shares, no par value per share | 150,000 | $0.50 | $75,450.00 |
DisclosureSEC source: 0001493152-19-014759 · ownership.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,255 F1 · price: Represents the weighted average price of shares purchased in multiple transactions at prices ranging from $0.4976 to $0.509, inclusive. The reporting person undertakes to provide to VBI Vaccines Inc., any security holder of VBI Vaccines Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 21, 2019 Filed Jun 25, 2019 00:32 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-19-000792 · form4-06242019_050657.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-21 F1 · derivative.exercise_date: Options vest 100% on June 21, 2020. Read SEC document |
| June 19, 2019 Filed Jun 19, 2019 12:17 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | PurchaseCommon Shares, no par value per share | 144,000 | $0.73 | $105,336.00 |
DisclosureSEC source: 0001493152-19-009422 · ownership.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,255 F1 · price: Represents the weighted average price of shares purchased in multiple transactions at prices ranging from $0.7199 to $0.748, inclusive. The reporting person undertakes to provide to VBI Vaccines Inc., any security holder of VBI Vaccines Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 16:14 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 31,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-19-009383 · ownership.xml · derivative · entry 2 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 31,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F2 · derivative.exercise_date: The restricted stock units vested 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date. F2 · derivative.expiration_date: The restricted stock units vested 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 16:14 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | Exercise / conversionCommon Shares, no par value per share | 31,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-19-009383 · ownership.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 17:17 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 450,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001493152-19-001340 · ownership.xml · derivative · entry 2 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Shares · 450,000 shares Expires 2029-01-31 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 31, 2019 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 31, 2019 (the "Option Agreement"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 17:17 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantCommon Shares, no par value per share | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-001340 · ownership.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,005 Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 20:38 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | PurchaseCommon Shares, no par value per share | 8,100 | $1.93 | $15,607.08 |
DisclosureSEC source: 0001493152-18-011114 · ownership.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,005 F1 · price: Represents the weighted average price of shares purchased in multiple transactions at prices ranging from $1.9267 to $1.929, inclusive. The reporting person undertakes to provide to VBI Vaccines Inc., any security holder of VBI Vaccines Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 11:06 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | PurchaseCommon Shares, no par value per share | 13,500 | $2.01 | $27,110.70 |
DisclosureSEC source: 0001493152-18-010980 · ownership.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,905 F1 · price: Represents the weighted average price of shares purchased in multiple transactions at prices ranging from $1.9956 to $2.1054, inclusive. The reporting person undertakes to provide to VBI Vaccines Inc., any security holder of VBI Vaccines Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 13:39 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | PurchaseCommon Shares, no par value per share | 16,800 | $2.28 | $38,236.80 |
DisclosureSEC source: 0001493152-18-010786 · ownership.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,405 F1 · price: Represents the weighted average price of shares purchased in multiple transactions at prices ranging from $2.21 to $2.32, inclusive. The reporting person undertakes to provide to VBI Vaccines Inc., any security holder of VBI Vaccines Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:11 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001415889-18-001030 · form4-06262018_020638.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-22 F1 · derivative.exercise_date: Options vest 100% on June 22, 2019. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 10:44 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 31,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-008812 · form4.xml · derivative · entry 2 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Shares · 31,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F2 · derivative.exercise_date: The restricted stock units vest 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date. F2 · derivative.expiration_date: The restricted stock units vest 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 10:44 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | Exercise / conversionCommon Shares, no par value per share | 31,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-008812 · form4.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. Read SEC document |
| May 24, 2018 Filed May 25, 2018 13:54 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | PurchaseCommon Shares, no par value per share | 11,000 | $2.99 | $32,890.00 |
DisclosureSEC source: 0001493152-18-007825 · form4.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,355 F1 · price: Represents the weighted average price of shares purchased in multiple transactions at prices ranging from $2.945 to $3.0099, inclusive. The reporting person undertakes to provide to VBI Vaccines Inc., any security holder of VBI Vaccines Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| May 11, 2018 Filed May 14, 2018 16:54 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | PurchaseCommon Shares, no par value per share | 7,100 | $2.91 | $20,661.00 |
DisclosureSEC source: 0001493152-18-006815 · form4.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,355 F1 · price: Represents the weighted average price of shares purchased in multiple transactions at prices ranging from $2.9088 to $2.919, inclusive. The reporting person undertakes to provide to VBI Vaccines Inc., any security holder of VBI Vaccines Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 14:26 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 150,000 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0001493152-18-001025 · form4.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 23, 2018 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 23, 2018 (the "Option Agreement"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 17:21 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | PurchaseCommon Shares, no par value per share | 4,609 | $3.88 | $17,882.92 |
DisclosureSEC source: 0001493152-17-014574 · form4.xml · nonDerivative · entry 2 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,255 Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 17:21 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | PurchaseCommon Shares, no par value per share | 5,391 | $3.89 | $20,970.99 |
DisclosureSEC source: 0001493152-17-014574 · form4.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,646 Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 14:31 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | PurchaseCommon Shares, no par value per share | 15,000 | $4.75 | $71,250.00 |
DisclosureSEC source: 0001493152-17-013934 · form4.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,255 Read SEC document |
| August 21, 2017 Filed Aug 22, 2017 16:20 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | PurchaseCommon Shares, no par value per share | 10,000 | $3.22 | $32,200.00 |
DisclosureSEC source: 0001493152-17-009728 · form4.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,255 F1 · price: Represents the weighted average price of shares purchased in multiple transactions at prices ranging from $3.18 to $3.24, inclusive. The reporting person undertakes to provide to VBI Vaccines Inc., any security holder of VBI Vaccines Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 16:42 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | PurchaseCommon Shares, no par value per share | 10,000 | $3.28 | $32,800.00 |
DisclosureSEC source: 0001493152-17-009246 · form4.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,255 F1 · price: Represents the weighted average price of shares purchased in multiple transactions at prices ranging from $3.21 to $3.33, inclusive. The reporting person undertakes to provide to VBI Vaccines Inc., any security holder of VBI Vaccines Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 20, 2017 Filed Jul 6, 2017 20:44 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001415889-17-001139 · form4-07062017_010743.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-20 F1 · derivative.exercise_date: Options vest 100% on June 20, 2018. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 17:53 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 31,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-17-006774 · form4.xml · derivative · entry 2 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Shares · 31,250 shares Expires 2026-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F2 · derivative.exercise_date: The restricted stock units vest 1/3 per year over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 17:53 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | Exercise / conversionCommon Shares, no par value per share | 31,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-17-006774 · form4.xml · nonDerivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. Read SEC document |
| April 18, 2017 Filed Apr 19, 2017 20:56 UTC | VBI VACCINES INC. VBIV · Entity 154844 | GrantOption (Right to Buy Common Shares) · Derivative | 20,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001493152-17-004199 · form4.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2027-01-26 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 26, 2017 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated April 18, 2017 (the "Option Agreement"). The options vest and become exercisable in 48 equal monthly installments beginning on the first day of the month following the Grant Date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| April 18, 2017 Filed Apr 27, 2017 21:56 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 20,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001493152-17-004496 · form4.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2027-01-26 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 26, 2017 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated April 18, 2017 (the "Option Agreement"). The options vest and become exercisable in 48 equal monthly installments beginning on the first day of the month following the Grant Date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 21:39 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001415889-16-007478 · form4-11182016_011158.xml · derivative · entry 1 Baxter Jeff · CIK 0001615941 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-11-16 F1 · derivative.exercise_date: Options vest 100% on November 16, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.